Sudden death in heart failure associated with reduced left ventricular function: substrates, mechanisms, and evidence-based management, Part II.
Sweeney
M O
MO
Cardiac Arrhythmia Service, Brigham and Women's Hospital, Boston, MA 02115, USA. mosweeney@partners.org
D000638:Amiodarone / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003645:Death, Sudden / Q000209:etiology / Q000517:prevention & control*; D004077:Digoxin / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D006333:Heart Failure / Q000150:complications* / Q000628:therapy*; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D007703:Peptidyl-Dipeptidase A / Q000627:therapeutic use; D018487:Ventricular Dysfunction, Left / Q000150:complications*
D000889:Anti-Arrhythmia Agents; D000451:Mineralocorticoid Receptor Antagonists; D004077:Digoxin; D007703:Peptidyl-Dipeptidase A; D000638:Amiodarone